Condition: Ventricular Tachycardia · Implantable Defibrillator User · ICD · Sponsor: Nova Scotia Health Authority
Ventricular tachycardia (VT) is a life-threatening cardiac rhythm disturbance which leads to sudden cardiac death (SCD), ventricular fibrillation, electrical storm, hemodynamic collapse, and syncope. VT patients with cardiomyopathy (diseased/scarred cardiac muscle) have the highest risk of SCD (\<1-4%) and recurrent VTs (15-35%). Although an implantable cardiac defibrillator (ICD) is the most effective treatment option to prevent SCD, it does not eliminate it. Without VT prevention, recurrent VT and ICD shocks may increase the risk of heart failure and death. The primary objective is to determine the optimal treatment strategy to maximize event-free survival among cardiomyopathy patients with ventricular tachycardia (VT) by the creation of a prospective, multicenter, longitudinal cohort. Also, the investigators will evaluate the epidemiology of VT, adherence to guidelines, safety, effectiveness, and cost-effectiveness of current treatment options for secondary prevention of VT in the real-world Canadian VT population.
This description comes directly from the study's public registry record.
John L Sapp, MD, FRCPC · 902-473-4272 · john.sapp@nshealth.ca
Suzanne E Greeley, BSCN · 902-473-2149 · suzanne.greeley@nshealth.ca
Always discuss trial participation with your own doctor first.
| Providence Health Care Society | Vancouver, British Columbia, Canada | Recruiting |
| QEII Health Science Centre | Halifax, Nova Scotia, Canada | Recruiting |
| Montreal Heart Institute, | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05835791